As of September 30, Rain had $77.3M in cash, cash equivalents and short-term investments. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We anticipate being able to provide a public update on our efforts before the end of the year.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RAIN:
- Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
- Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
- Rain Oncology confirms receipt of unsolicited proposal from Concentra
- Rain Oncology price target lowered to $1 from $1.50 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue